皮质类固醇治疗临床研究中胃肠道不良反应报告的特征分析
该研究评估了先前一项荟萃分析纳入的159项研究是否按照CONSORT Harms扩展版报告胃肠道出血或穿孔,并分析报告质量与资金来源、期刊及发表年份的关联。结果显示平均CONSORT Harms评分为5.25/10(标准差±2.09),多数研究报告了参与者退出(133项,83.6%)、胃肠道出血或穿孔的绝对风险(130项,81.8%)及伤害信息收集方式(118项,74.2%)。胃肠道出血或穿孔的报告随评分升高而增加(OR 1.173,P=0.042),未发现评分与发表年份或资金来源显著相关,但在主要医学期刊发表的研究有评分更高的趋势(评分差异0.78,P=0.052)。
要点
- 平均CONSORT Harms评分为5.25/10(标准差±2.09),仅少数研究获高分。
- 多数研究报告了参与者退出、胃肠道出血或穿孔绝对风险及伤害信息收集方式。
- 胃肠道出血或穿孔的报告随CONSORT Harms评分升高而增加(OR 1.173,P=0.042)。
核心结论
- 系统评价中少数研究使用CONSORT Harms标准获得高分。
- 多数研究报告了关于胃肠道出血或穿孔风险的最重要标准。
- 由于文本不精确和标准模糊,评价者一致性差异大。
- 若无合格判断,常规按CONSORT Harms推荐完成情况评分是不可取的。
研究设计与样本
- 对先前一项荟萃分析纳入的159项研究进行评估,评价其对CONSORT Harms推荐清单的符合程度、资金来源、发表类型和年份。
- 通过比较每项研究的评分来评估评价者间一致性。
主要发现
- 平均CONSORT Harms评分为5.25/10(标准差±2.09)。
- 133项研究(83.6%)报告了参与者退出信息,130项(81.8%)报告了胃肠道出血或穿孔的绝对风险,118项(74.2%)报告了伤害相关信息的收集方式。
- 胃肠道出血或穿孔的报告随评分升高而增加(OR 1.173,P=0.042)。
- CONSORT Harms评分与发表年份或资金来源无显著关联,但在主要医学期刊发表的研究有评分更高的趋势(评分差异0.78,P=0.052)。
- 不同研究间胃肠道出血的定义存在差异。
关键数值与推荐
- 平均CONSORT Harms评分5.25/10(标准差±2.09)。
- 报告参与者退出:133项研究(83.6%)。
- 报告胃肠道出血或穿孔绝对风险:130项研究(81.8%)。
- 报告伤害相关信息收集方式:118项研究(74.2%)。
- 胃肠道出血或穿孔报告与评分的关联:OR 1.173,P=0.042。
临床怎么用
- 常规按CONSORT Harms推荐完成情况评分需结合合格判断,否则不可取。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine whether 159 studies included in a previous meta-analysis reported on gastrointestinal bleeding or perforation in accordance with the CONSORT extension for reporting harms outcomes (CONSORT Harms recommendations checklist); whether differences were associated with funding source, journal, or publication year; and whether the CONSORT Harms checklist is a suitable tool for evaluation of adverse effects reporting. STUDY DESIGN AND SETTING: Articles were assessed for fulfillment of the CONSORT Harms recommendations, funding source, publication type, and year. Agreement between reviewers was assessed by comparing scores for each study. RESULTS: The mean CONSORT Harms score was 5.25 out of 10 (standard deviation ± 2.09). Most studies included information on participant withdrawals (133 studies, 83.6%), absolute risk of gastrointestinal bleeding or perforation (130 studies, 81.8%), and how harms-related information was collected (118 studies, 74.2%). Reporting of gastrointestinal bleeding or perforation increased with higher scores (odds ratio 1.173, P = 0.042). There was no significant association between CONSORT Harms score achieved and publication year or funding source, but there was a trend toward higher scores in studies published in the major medical journals (score difference 0.78, P = 0.052). Definitions of gastrointestinal bleeding differed between studies. Reviewer agreement was fair to moderate with large variations. CONCLUSION: Few studies in the systematic review received high scores using the CONSORT Harms criteria. Most studies reported on the most important criteria regarding risk of gastrointestinal bleeding or perforation. Reviewer agreement showed large variations due to imprecise texts and ambiguous criteria. Routine scoring according to fulfillment of the CONSORT Harms recommendations would be inadvisable without qualified judgment.
引用
- Westergren T, Narum S, Klemp M, et al. Characterization of gastrointestinal adverse effects reported in clinical studies of corticosteroid therapy. J Clin Epidemiol. 2017. PMID: 29113937. doi:10.1016/j.jclinepi.2017.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。